Lung Cancer
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non- Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536) (M24-536)
- Details
ClinicalTrials.gov ID:
NCT06772623
Diagnosis Type:
NA
USOR Number:
- Address
,
P: